Myocardial injury and COVID-19: Possible mechanisms

Savalan Babapoor-Farrokhran, Deanna Gill, Jackson Walker, Roozbeh Tarighati Rasekhi, Behnam Bozorgnia, Aman Amanullah, Savalan Babapoor-Farrokhran, Deanna Gill, Jackson Walker, Roozbeh Tarighati Rasekhi, Behnam Bozorgnia, Aman Amanullah

Abstract

Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia.

Keywords: Cardiovascular disease; Coronavirus Disease 2019; Mechanisms of myocardial injury; Myocardial injury; Myocarditis; Severe Acute Respiratory Syndrome Coronavirus-2.

Conflict of interest statement

Declaration of competing interest None declared.

Copyright © 2020 Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract

References

    1. COVID-19 Map. In: Johns Hopkins Coronavirus Resource Center [Internet]. [cited 9 Apr 2020]. Available: .
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.
    1. Zumla A., Niederman M.S., Zumla A. The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security. Curr. Opin. Pulm. Med. 2020;26(3):193–196.
    1. Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? Arab J. Gastroenterol. 2020 doi: 10.1016/j.ajg.2020.03.002.
    1. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab. Syndr. 2020;14(3):247–250.
    1. Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1286.
    1. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020 doi: 10.1007/s00059-020-04909-z.
    1. Li W., Hulswit R.J.G., Kenney S.P., Widjaja I., Jung K., Alhamo M.A., Moyasar A., van Dieren B., van Kuppeveld F.J.M., Saif L.J., Bosch B.J. Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility. Proc. Natl. Acad. Sci. U. S. A. 2018;115:E5135–E5143.
    1. Zhang S.F., Tuo J.L., Huang X.B., Zhu X., Zhang D.M., Zhou K., Yuan L., Luo H.J., Zheng B.J., Yuen K.Y., Li M.F., Cao K.Y., Xu L. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010–2015 in Guangzhou. PLoS One. 2018;13
    1. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
    1. Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637.
    1. Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann. Saudi Med. 2016;36:78–80.
    1. Oudit G.Y., Kassiri Z., Jiang C., Liu P.P., Poutanen S.M., Penninger J.M., Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Investig. 2009;39:618–625.
    1. Li S.S., Cheng C.W., Fu C.L., Chan Y.H., Lee M.P., Chan J.W., Yiu S.F. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003;108:1798–1803.
    1. Yu C.M., Wong R.S., Wu E.B., Kong S.L., Wong J., Yip G.W., Soo Y.O., Chiu M.L., Chan Y.S., Hui D., Lee N., Wu A., Leung C.B., Sung J.J. Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J. 2006;82:140–144.
    1. Wu C.I., Postema P.G., Arbelo E., Behr E.R., Bezzina C.R., Napolitano C., Robyns T., Probst V., Schulze-Bahr E., Remme C.A., Wilde A.A.M. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020 doi: 10.1016/j.hrthm.2020.03.024.
    1. He X.W., Lai J.S., Cheng J., Wang M.W., Liu Y.J., Xiao Z.C., Xu C., Li S.S., Zeng H.S. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E011.
    1. Badawi A., Ryoo S.G. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int. J. Infect. Dis. 2016;49:129–133.
    1. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020 doi: 10.1016/j.ijid.2020.03.017.
    1. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020 doi: 10.1007/s00392-020-01626-9.
    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1017.
    1. Boyette L.C., Manna B. StatPearls Publishing; Treasure Island (FL): 2019. Physiology, Myocardial Oxygen Demand. StatPearls.
    1. Xiong T.-Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020 doi: 10.1093/eurheartj/ehaa231.
    1. Adão R. Inside the heart of COVID-19. Cardiovasc. Res. 2020 doi: 10.1093/cvr/cvaa086.
    1. Meng X., Yang J., Dong M., Zhang K., Tu E., Gao Q., Chen W., Zhang C., Zhang Y. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 2016;13((3)B):167–179.
    1. Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Bondi-Zoccai G., Brown T.S., Nigoghossian C.D., Zidar D.A., Haythe J., Brodie D., Beckman J.A., Kirtane A.J., Stone G.W., Krumholz H.M., Parikh S.A. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J. Am. Coll. Cardiol. 2020 doi: 10.1016/j.jacc.2020.03.031.
    1. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D.S. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa248.
    1. Fioranelli M., Bottaccioli A.G., Bottaccioli F., Bianchi M., Rovesti M., Roccia M.G. Stress and inflammation in coronary artery disease: a review psychoneuroendocrineimmunology-based. Front. Immunol. 2018;9:2031.
    1. Caution Recommended on COVID-19 Treatment with Hydroxychloroquine and Azithromycin for Patients with Cardiovascular Disease. In: American Heart Association [Internet]. [cited 9 Apr 2020]. Available: .
    1. Chen C., Jiangtao Y., Ning Z., Jianping Z., Daowen W. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese J Cardiol. 2020;48:E008.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 doi: 10.1001/jama.2020.1585.
    1. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H., Yang B., Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.0950.
    1. Zeng J.H., Yingxia L., Yuan J., Wang F., Wu W.B., Li J.X., Wang L.F., Gao H., Qu J.X., Wang Y., Dong C.F., Luo Y.F., Zhou D., Feng W.X., Feng C., Lei L. Clinical characteristics and cardiac injury description of 419 cases of COVID-19 in Shenzhen, China. Lancet. 2020 doi: 10.2139/ssrn.3556659. Preprint, available at.
    1. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05991-x.
    1. Caforio A.L.P., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B., Fu M., Heliö T., Heymans S., Jahns R., Klingel K., Linhart A., Maisch B., McKenna W., Mogensen J., Pinto Y.M., Ristic A., Schultheiss H.P., Seggewiss H., Tavazzi L., Thiene G., Yilmaz A., Charron P., Elliott P.M. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013;34:2636–2648.
    1. O’Connell J.B., Topol E.J. In: Cardiovascular Medicine. Topol E.J., Nissen J., editors. Lipincott-Raven; Philadelphia: 1998. Diagnosis and medical treatment of inflammatory cardiomyopathy.
    1. Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D.S., Cerini M., Farina D., Gavazzi E., Maroldi R., Adamo M., Ammirati E., Sinagra G., Lombardi C.M., Metra M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1096.
    1. Fried J.A., Ramasubbu K., Bhatt R., Topkara V.K., Clerkin K.J., Horn E., Rabbani L., Brodie D., Jain S.S., Kirtane A., Masoumi A., Takeda K., Kumaraiah D., Burkhoff D., Leon M., Schwartz A., Uriel N., Sayer G. The variety of cardiovascular presentations of COVID-19. Circulation. 2020 doi: 10.1161/CIRCULATIONAHA.120.047164.
    1. Ma K.L., Liu Z.H., Cao C.F., Liu M.K., Liao J., Zou J.B., Kong L.X., Wan K.Q., Zhang J., Wang Q.B., Tian W.G., Qin G.M., Zhang L Luan F.J., Li S.L., Hu L.B., Li Q.L., Wang H.Q. COVID-19 myocarditis and severity factors: an adult cohort study. medRxiv. 2020 doi: 10.1101/2020.03.19.20034124. (preprint server). Preprint, available at.
    1. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., da Costa J., Zhang L., Pei Y., Scholey J., Ferrario C.M., Manoukian A.S., Chappell M.C., Backx P.H., Yagil Y., Penninger J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828.
    1. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47:718–726.
    1. Oudit G.Y., Kassiri Z., Patel M.P., Chappell M., Butany J., Backx P.H., Tsushima R.G., Scholey J.W., Khokha R., Penninger J.M. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007;75:29–39.
    1. Zhao X., Nicholls J.M., Chen Y.-G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-β signaling. J. Biol. Chem. 2008;283:3272–3280.
    1. Cameron M.J., Ran L., Xu L., Danesh A., Bermejo-Martin J.F., Cameron C.M., Muller M.P., Gold W.L., Richardson S.E., Poutanen S.M., Willey B.M., DeVries M.E., Fang Y., Seneviratne C., Bosinger S.E., Persad D., Wilkinson P., Greller L.D., Somogyi R., Humar A., Keshavjee S., Louie M., Loeb M.B., Brunton J., McGeer A.J., Canadian SARS Research Network, Kelvin D.J. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007;81:8692–8706.
    1. Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008;133:13–19.
    1. Wong C.K., Lam C.W., Wu A.K., Ip W.K., Lee N.L.S., Chan I.H.S., Lit L.C., Hui D.S., Chan M.H., Chung S.S., Sung J.J. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95–103.
    1. Norman J., Bar-Yam Y., Taleb N.N. New England Complex Systems Institute; 2020. Systemic Risk of Pandemic Via Novel Pathogens—Coronavirus: A Note.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe